PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer.
Yoon-Koo KangJeong Hwan YookYoung-Kyu ParkJong Seok LeeYoung-Woo KimJin Young KimMin-Hee RyuSun Young RhaIk Joo ChungIn-Ho KimSang Cheul OhYoung Soo ParkTaeil SonMi Ran JungMi Hwa HeoHark Kyun KimChoHyun ParkChang Hak YooJin-Hyuk ChoiDae Young ZangYou-Jin JangJi Young SulJong Gwang KimBeom Su KimSeung-Hoon BeomSang Hee ChoSeung-Wan RyuMyeong-Cheorl KookBaek-Yeol RyooHyun Ki KimMoon-Won YooNam Su LeeSang Ho LeeGyunji KimYeonJu LeeJee Hyun LeeSung Hoon NohPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
PRODIGY showed that neoadjuvant DOS chemotherapy, as part of perioperative chemotherapy, is effective and tolerable in Korean patients with LAGC.
Keyphrases